Sivik Global Healthcare LLC Buys New Position in Zimmer Biomet Holdings, Inc. $ZBH

Sivik Global Healthcare LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 40,000 shares of the medical equipment provider’s stock, valued at approximately $3,940,000. Zimmer Biomet accounts for 1.1% of Sivik Global Healthcare LLC’s portfolio, making the stock its 26th biggest holding.

A number of other hedge funds also recently made changes to their positions in ZBH. Absher Wealth Management LLC purchased a new position in shares of Zimmer Biomet in the third quarter valued at $2,344,000. Gries Financial LLC lifted its holdings in Zimmer Biomet by 30.4% in the 3rd quarter. Gries Financial LLC now owns 21,058 shares of the medical equipment provider’s stock worth $2,074,000 after buying an additional 4,910 shares in the last quarter. Global Retirement Partners LLC boosted its position in Zimmer Biomet by 7.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 111 shares during the last quarter. Physicians Financial Services Inc. acquired a new stake in shares of Zimmer Biomet during the third quarter valued at about $210,000. Finally, Generali Asset Management SPA SGR increased its position in shares of Zimmer Biomet by 0.9% during the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after acquiring an additional 122 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $94.86 on Wednesday. Zimmer Biomet Holdings, Inc. has a 12 month low of $85.33 and a 12 month high of $114.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The stock has a fifty day moving average price of $92.44 and a 200 day moving average price of $96.60. The company has a market cap of $18.80 billion, a P/E ratio of 23.48, a PEG ratio of 2.36 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the previous year, the company posted $1.74 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Analysts Set New Price Targets

A number of research analysts recently commented on ZBH shares. Evercore ISI raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their price target for the company from $94.00 to $120.00 in a report on Monday. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 18th. Canaccord Genuity Group cut their price target on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Citigroup decreased their price objective on shares of Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a report on Thursday, December 11th. Finally, Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $108.30.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.